DRRX (DURECT Corp) Market Value to Book Value Ratio

Official company branding of durect.com (DRRX)

This daily price chart for DURECT Corporation (DRRX) confirms the influence of factors where the metric stands at 17.49. The business leverages AI systems and robotics to accelerate the bioscreening of formulas. Stability is driven by the development of organ recovery methods and proprietary delivery systems. However, uncertainty regarding test results creates a risk of dependency on FDA decisions, forcing the company to strictly limit its capital expenditure.

DRRX durect.com: Market Value to Book Value in the range 07/04/2022 - 09/27/2025

Financial and market metric breakdowns for DURECT Corporation (DRRX)

- price and consensus price forecast:
Stock Quotes durect.com|DRRX - Broker Consensus Forecast
- market capitalization data:
Market Value DURECT Corp.|DRRX - Full Business Value
- book capitalization data:
Book Value per Share DURECT|DRRX - Accounting Value of Company|Market Capitalization to Book Value Ratio durect.com|DRRX - Company Total Assets
- debt and liquidity data:
Debt to Equity DURECT Corporation|DRRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity durect.com|DRRX - Company Total Debt|Debts to Book Capitalization DURECT Corp.|DRRX - Company Long-Term Debts|Company Current Liabilities DURECT
Initial company analysis:DURECT Corp - DRRX
Original product of durect.com

The specifics of DURECT Corporation (DRRX) are driven by colossal R&D expenditures and stringent FDA oversight. This indicator measures the gap between market value and net assets, revealing the extent of the speculative premium. A rising ratio signals inflated market expectations regarding future patents. High values increase the risk of a sharp correction in the event of failed trials. The historical relationship between market cap and book value objectively reflects the current overvaluation of the business.

Main competitors

Market Cap to Net Assets Ratio Arrowhead Pharmaceuticals|MIRM (mirumpharma.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio dynavax.com DVAX|Market Capitalization to Net Assets Arbutus Biopharma Corp|Inventiva Pharma (IVA) - Market Capitalization to Book Value Ratio|Market Value to Book Value Gyre Therapeutics Corp. (GYRE)|Market Capitalization to Book Value Ratio ASMB (Assembly Biosciences)|Galectin Therapeutics, Inc. - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Genfit Corp (GNFT)|ALGS: Market Value to Book Value|BIVI (biovieinc.com) - Market Value to Book Value Ratio|Galmed Pharmaceuticals Ltd. (GLMD) - Market Cap to Net Assets Ratio|NDRA (ENDRA Life Sciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Hepion Pharma (HEPA)